Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 16, 2023
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
[ Thu, Feb 16th 2023
] - WOPRAI
Tejas Savant Maintained (ADPT) at Hold with Decreased Target to $15 on, Feb 16th, 2023
Tejas Savant of Morgan Stanley, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Hold with Decreased Target from $16 to $15 on, Feb 16th, 2023.
Tejas has made no other calls on ADPT in the last 4 months.
There are 3 other peers that have a rating on ADPT. Out of the 3 peers that are also analyzing ADPT, 0 agree with Tejas's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Tejas
- Dan Leonard of "Credit Suisse" Reiterated at Sell and Held Target at $7 on, Wednesday, February 15th, 2023
- Sung Ji Nam of "Scotiabank" Initiated at Buy and Held Target at $15 on, Thursday, January 5th, 2023
- David Westenberg of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $14 on, Wednesday, December 21st, 2022
